These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38760543)

  • 21. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
    Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
    PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.
    Lang X; Green MD; Wang W; Yu J; Choi JE; Jiang L; Liao P; Zhou J; Zhang Q; Dow A; Saripalli AL; Kryczek I; Wei S; Szeliga W; Vatan L; Stone EM; Georgiou G; Cieslik M; Wahl DR; Morgan MA; Chinnaiyan AM; Lawrence TS; Zou W
    Cancer Discov; 2019 Dec; 9(12):1673-1685. PubMed ID: 31554642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
    Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-35 Dampens CD8
    Yang L; Shao X; Jia S; Zhang Q; Jin Z
    Front Immunol; 2019; 10():1032. PubMed ID: 31134088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asiaticoside promoted ferroptosis and suppressed immune escape in gastric cancer cells by downregulating the Wnt/β-catenin pathway.
    Ye C; Yao Z; Wang Y; Zhang C
    Int Immunopharmacol; 2024 Jun; 134():112175. PubMed ID: 38733821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Baicalin induces ferroptosis in HepG2 cells by inhibiting ROS-mediated PI3K/Akt/FoxO3a signaling pathway].
    Zhou JQ; Li HJ; Zeng YH; Chen HH; Liang WY; Zhang J; Ding FP
    Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(5):1327-1334. PubMed ID: 38621980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.
    Fan Z; Yang G; Zhang W; Liu Q; Liu G; Liu P; Xu L; Wang J; Yan Z; Han H; Liu R; Shu M
    J Cell Mol Med; 2021 Nov; 25(21):10197-10212. PubMed ID: 34609072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
    Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
    Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
    Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
    Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
    Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
    Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
    Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma.
    Liu ZL; Zhu LL; Liu JH; Pu ZY; Ruan ZP; Chen J
    Aging (Albany NY); 2020 Nov; 12(24):25172-25188. PubMed ID: 33223512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.
    Huang Y; Peng M; Yu W; Li H
    Int Immunopharmacol; 2024 Sep; 138():112534. PubMed ID: 38941667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver cancer in ovo models for preclinical testing.
    Garcia P; Wang Y; Viallet J; Mehdi NEH; Montaut E; Decaens T; Emadali A; Macek Jílková Z
    FASEB J; 2024 Sep; 38(17):e70029. PubMed ID: 39215630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The epigallocatechin gallate derivative Y
    Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
    J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.